OncoMatch/Clinical Trials/NCT06863233
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
Is NCT06863233 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Zirconium Zr 89 crefmirlimab berdoxam for lung cancer.
Treatment: Zirconium Zr 89 crefmirlimab berdoxam — The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Prior therapy
Must have received: engineered TIL cell therapy — enrolled but not yet treated
Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not received the treatment yet.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (Consent Only) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Consent Only) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Consent Only) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only) · Commack, New York
- Memorial Sloan Kettering Westchester (Consent only) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06863233 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received engineered TIL cell therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages